Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)
Close on Nov 18, 2026Market cap $226.67MP/E –Yield –
Immuneering price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Immuneering's price to sales ratio was 407.1× on Feb 28, 2023, against 48.9× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Feb 28, 2023 | 407.1× | +154.9 |
| 2022 | Dec 30, 2022 | 252.2× | +199.7 |
| 2021 | Dec 31, 2021 | 52.4× | – |
See a number that looks wrong?